Skip to main content
SpringerLink
Log in

Therapeutic drug monitoring as an essential tool to ensure clozapine efficacy and prevent its toxicity in smokers: a case report

  • Correspondence
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Figure 1 was obtained from our pharmacological and toxicological laboratory work (dosage of drug and its metabolite in patient’s plasma) and clinical observation of the patient (daily consumption of cigarettes). Relating data are available in an Excel sheet from the corresponding author on request.

Abbreviations

Clo:

Clozapine

C/D:

Concentration/dose ratio

CYP 1A2:

Cytochrome P450 1A2

NClo:

Norclozapine

PAH:

Polycyclic aromatic hydrocarbons

TDM:

Therapeutic drug monitoring

References

  1. Résumé des caractéristiques du produit - LEPONEX 25 mg, comprimé sécable - Base de données publique des médicaments. https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=67513540&typedoc=R#HautDePage. Accessed 4 Oct 2022

  2. Correll CU, Howes OD (2021) Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry82(5):MY20096AH1C. https://doi.org/10.4088/JCP.MY20096AH1C

  3. Wagner S, Varet-Legros MG, Fabre C, Montastruc JL, Bagheri H (2011) Confounding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies? Eur J Clin Pharmacol 67(5):533–534. https://doi.org/10.1007/s00228-010-0925-z

    Article  PubMed  Google Scholar 

  4. Siskind D, Sharma M, Pawar M et al (2021) Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis. Acta Psychiatr Scand 144(5):422–432. https://doi.org/10.1111/acps.13361

    Article  CAS  PubMed  Google Scholar 

  5. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H (2006) The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 62(12):1049–1053. https://doi.org/10.1007/s00228-006-0209-9

    Article  CAS  PubMed  Google Scholar 

  6. Molden E, Spigset O (2009) Tobacco smoking and drug interactions. Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke 129(7):632–633. https://doi.org/10.4045/tidsskr.08.0122

    Article  Google Scholar 

  7. Perlík F (2017) Smoking and pharmacological interactions. Cas Lek Cesk 156(1):13–14

    PubMed  Google Scholar 

  8. Taylor D (1997) Pharmacokinetic interactions involving clozapine. Br J Psychiatry J Ment Sci 171:109–112. https://doi.org/10.1192/bjp.171.2.109

    Article  CAS  Google Scholar 

  9. van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13(3):169–172. https://doi.org/10.1097/00008571-200303000-00006

    Article  PubMed  Google Scholar 

  10. Wagner E, McMahon L, Falkai P, Hasan A, Siskind D (2020) Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta Psychiatr Scand 142(6):456–466. https://doi.org/10.1111/acps.13228

    Article  CAS  PubMed  Google Scholar 

  11. Plowchalk DR, Rowland YK (2012) Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol 68(6):951–960. https://doi.org/10.1007/s00228-011-1189-y

    Article  CAS  PubMed  Google Scholar 

  12. Montville DJ, Lindsey JM, Leung JG (2021) Fluctuation between cigarette smoking and use of electronic nicotine delivery systems: impact on clozapine concentrations and clinical effect. Ment Health Clin 11(6):365–368. https://doi.org/10.9740/mhc.2021.11.365

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 17(3):141–143. https://doi.org/10.1097/00004850-200205000-00008

    Article  CAS  PubMed  Google Scholar 

  14. Varma S, Bishara D, Besag FMC, Taylor D (2011) Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 1(2):47–66. https://doi.org/10.1177/2045125311405566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51(1–02):9–62. https://doi.org/10.1055/s-0043-116492

    Article  CAS  PubMed  Google Scholar 

  16. de Leon J (2020) Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology168:107656. https://doi.org/10.1016/j.neuropharm.2019.05.033

  17. Couchman L, Morgan PE, Spencer EP, Flanagan RJ (2010) Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit 32(4):438–447. https://doi.org/10.1097/FTD.0b013e3181dad1fb

    Article  CAS  PubMed  Google Scholar 

  18. Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21(6):569–574. https://doi.org/10.1097/00004714-200112000-00005

    Article  CAS  PubMed  Google Scholar 

  19. McCarthy RH (1994) Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 27(5):210–211. https://doi.org/10.1055/s-2007-1014307

    Article  CAS  PubMed  Google Scholar 

  20. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27(4):539–543. https://doi.org/10.1097/01.ftd.0000164609.14808.93

    Article  CAS  PubMed  Google Scholar 

  21. Perry PJ, Bever KA, Arndt S, Combs MD (1998) Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44(8):733–738. https://doi.org/10.1016/s0006-3223(97)00531-3

    Article  CAS  PubMed  Google Scholar 

  22. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24(1):70–78. https://doi.org/10.1097/01.jcp.0000106221.36344.4d

    Article  CAS  PubMed  Google Scholar 

  23. Singh RK, Dai Y, Staudinger JL, Muma NA (2009) Activation of the JAK-STAT pathway is necessary for desensitization of 5-HT2A receptor-stimulated phospholipase C signalling by olanzapine, clozapine and MDL 100907. Int J Neuropsychopharmacol 12(5):651–665. https://doi.org/10.1017/S1461145708009590

    Article  CAS  PubMed  Google Scholar 

  24. Qiao J, Li H, Li M (2013) Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 38(3):513–524. https://doi.org/10.1038/npp.2012.213

    Article  CAS  Google Scholar 

  25. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ (1999) Serotonin-6 receptor variant (C267T) and clinical response to clozapine. NeuroReport 10(6):1231–1233. https://doi.org/10.1097/00001756-199904260-00014

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Clinical Toxicology, Pharmacovigilance and Addictovigilance (CEIP-A), Regional University Hospital of Nancy, Vandoeuvre-les-Nancy, France

    Mélissa Yéléhé-Okouma, Sophie Charrois-Sciaudeau & Nicolas Gambier

  2. Department of Neurology, Regional University Hospital of Nancy, Vandoeuvre-les-Nancy, France

    Louise Tyvaert

  3. Unity of Clinical Psychiatry, Regional Institute of Physical Rehabilitation, Nancy, France

    Nadine Bertoni

  4. University of Lorraine-CNRS, IMoPA, Vandoeuvre-les-Nancy, France

    Nicolas Gambier

Authors
  1. Mélissa Yéléhé-Okouma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Charrois-Sciaudeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Louise Tyvaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nadine Bertoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Gambier
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LT took care of the patient for the management of the seizures. NB took care of the patient for the management of clozapine treatment adjustment. MYO and NB had the idea for the article, performed the literature search, and specifically contributed to the acquisition, analysis, and interpretation of clinical data. MYO, SCS, and NG specifically contributed to the acquisition, analysis, and interpretation of analytic data. Each author contributed to the conception, drafting, revision of the work, and approved the final version.

Corresponding author

Correspondence to Mélissa Yéléhé-Okouma.

Ethics declarations

Consent for publication

The patient’s guardian has consented to submitting the case report to the journal.

Competing interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yéléhé-Okouma, M., Charrois-Sciaudeau, S., Tyvaert, L. et al. Therapeutic drug monitoring as an essential tool to ensure clozapine efficacy and prevent its toxicity in smokers: a case report. Eur J Clin Pharmacol 79, 1713–1715 (2023). https://doi.org/10.1007/s00228-023-03574-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-023-03574-5

Search

Navigation